In patients with T2D, all pre-treatments significantly reduced HDNs adhesion to hECM by up to 74% (p < 0.001) versus PBS pre-treatment, and only the combination of anti-CD18 and DNase I significantly reduced HDN adhesion by 56% compared to DNase I (p < 0.05; Figure 5B). This evidence concerns the gene ITGB2 and type 2 diabetes mellitus.